Garrett Vygantas, M.D.

Ceria was founded to develop products from a proprietary platform technology to treat life-threatening human diseases characterized by overactive and dysregulated immune responses. Cerias platform technology consists of a novel active pharmaceutical agent comprised of a regulatory microRNA (miR-146a) conjugated to cerium nanoparticles (CNPs). Like all nanoparticles, CNPs are actively endocytosed by all cells they contact, delivering the miR-146a payload to targeted cells. Multiple high morbidity and life-threatening conditions are characterized by dysregulated immune responses including acute respiratory distress syndrome (ARDS), diabetic foot ulcers (DFU) and ulcerative colitis (UC), representing a US market of $4B. Affected tissues in these conditions all demonstrate reduce miR-146a and are corrected by our candidate drug products. Development to date has been supported by ~$7.5m of nondilutive financing and $500k investment capital. The company is seeking up to $3m in investment capital to contribute to a first-in-man clinical study of one drug product consisting of formulated CNP-miR-146a in DFU.

CellFE is a cell engineering startup that enables development and manufacturing of the new generation of medicines – cell therapies. CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering –efficiently delivering gene-editing molecules into cells while preserving cell viability. CellFE’s technology: • Enables development of previously inaccessible cell therapies by providing means for transporting hard-to-deliver molecules into the cells. • Accelerates commercialization of existing cell therapies by significantly reducing cost, complexity, and processing time, while improving the efficacy and safety of the cell engineering process.

Genomenon is a leading genomic intelligence company dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer. Blending the power of AI with genomic expertise, Genomenon simplifies complex genetic data into actionable insights for patient diagnosis and precision medicine development. The company’s solutions include software, data, and services. Genomenon offers advanced genomic software solutions designed to streamline and enhance genetic research and clinical decision-making. Our flagship product, the Mastermind® Genomic Intelligence Platform, provides comprehensive genomic data integration and analysis, offering researchers and clinicians a powerful tool to interpret genetic variants and their clinical relevance. Complementing this is the Cancer Knowledgebase (CKB), which focuses specifically on the landscape of somatic mutations, offering curated, actionable insights to support oncology research and personalized cancer treatment. Together, these platforms aim to accelerate discoveries and improve patient outcomes through sophisticated data analysis and knowledge integration.

Mediphage is a biotech company developing non-viral safe and redosable gene therapies. ministring DNA (msDNA), which is Mediphage’s flagship technology, is a versatile linear covalently closed (LCC) DNA construct that can accommodate large transgenes (> 4.7 kb) and address various applications. The company is evaluating the therapeutic potential of its non-viral platform technology in a number of indications internally and through external collaborations.

Inflammatix, Inc., based in Sunnyvale, California, USA, is revolutionizing molecular diagnostics with machine-learning-powered technology to rapidly read a patient’s immune response to improve patient care and reduce major public health burdens. It’s flagship in vitro diagnostic (IVD) test, the TriVerity™ Test System (“TriVerity”) shows the likelihood of a bacterial infection, a viral infection, and illness severity in adult patients with suspected acute infection or sepsis that present to emergency departments. TriVerity empowers physicians to confidently make care decisions, which could influence the selection of antimicrobial therapy, focused workups with judicious laboratory and imaging orders, and patient admission or discharge disposition. TriVerity and future tests are designed to be performed on the company’s proprietary Myrna™ instrument, a cartridge-based benchtop analyzer that is capable of multiplex sample-to-answer quantitation of mRNA in about 30 minutes.

Exo (pronounced “Echo”) is a medical imaging software and devices company. Exo believes everyone around the world should have access to high-quality, affordable and easy-to-use medical imaging. The company is on a mission to modernize medical imaging through its high-performance ultrasound platform and artificial intelligence. Exo’s goal is to enable healthcare professionals to make critical, real-time decisions that ultimately improve patient outcomes. Our powerful ecosystem combines high-performance imaging, FDA-cleared AI and workflow software thats designed to make medical imaging as simple as using a smartphone.

Level Ex®, the world’s leading medical video game studio, creates games played by more than one million clinicians. Our team uses state-of-the-art video game technology and cognitive neuroscience to capture the challenges of practicing medicine— transforming how medical professionals advance their skills, earn CME, and stay up-to-date on new medical devices, drug therapies, and clinical best practices. Our medical video games run on any device, anywhere, anytime. Top 20 pharma and medical device companies, medical societies, and government organizations including NASA, leverage Level Ex’s award-winning technology for education and training.

Gauss is the leader in computer vision in healthcare. Founded in 2011, Gauss’s mission is to digitally augment clinicians with software that radically improves diagnostic accuracy and leads to improved patient safety and clinical outcomes. Gauss’s flagship product, Triton, leverages computer vision to detect surgical and obstetric hemorrhage in real time and notifies clinicians who can enact timely intervention and treatment. Triton was granted De Novo clearance from the U.S. Food and Drug Administration (FDA) in 2014, as the first-ever computer vision software for surgical use, and several follow-on 510(k) clearances. Available on the iPhone, Triton has been widely adopted by health systems in the United States and is a recipient of the Apple Design Award, which recognizes the best in design, innovation and technology on Apple platforms. Gauss was acquired by Stryker (NYSE: SYK) in 2021. For more information, visit http://www.gauss.com.

Our applied generative AI solutions help healthcare providers make more informed decisions quickly to improve patient care and outcomes, while reducing costs, manual effort, and alleviating resource pressures.

Doctor On Demand is now part of Included Health, delivering integrated virtual care and navigation. We’re on a mission to raise the standard of healthcare for everyone. We break down barriers to provide high-quality care for every person in every community — no matter where they are in their health journey or what type of care they need, from acute to chronic, behavioral to physical. We offer our members care guidance, advocacy, and access to personalized virtual and in-person care for everyday and urgent care, primary care, behavioral health, and specialty care. It’s all included.

MD Revolution’s intuitive RevUp platform and expert clinical team work in tandem to optimize healthcare outcomes, ensuring sustained patient engagement by eliminating gaps in care. Our widely tested and approved procedures first assess your practice’s available technology and present workflow, and in turn implement programs which are both intuitive to patients and designed to act as an extension of your practice. By providing customized, turnkey solutions, our programs effortlessly surpass any and all obstacles traditionally associated with remote care. MD Revolution’s clinical teams are experts in designing and implementing programs for Chronic Care Management (CCM), Behavioral Health Integration (BHI) and Remote Patient Monitoring (RPM), all while increasing revenue to your practice through fee-for service codes.

AVIA is the nation’s leading digital transformation partner for healthcare organizations, providing unparalleled opportunities for industry leaders to collaborate, access market intelligence, and drive strategic innovation. Through the AVIA Network and AVIA Marketplace, healthcare leaders can leverage proven collaborative tools and results-based consulting to address the industry’s most pressing challenges. Learn more about AVIA at aviahealth.com.

Ceria was founded to develop products from a proprietary platform technology to treat life-threatening human diseases characterized by overactive and dysregulated immune responses. Cerias platform technology consists of a novel active pharmaceutical agent comprised of a regulatory microRNA (miR-146a) conjugated to cerium nanoparticles (CNPs). Like all nanoparticles, CNPs are actively endocytosed by all cells they contact, delivering the miR-146a payload to targeted cells. Multiple high morbidity and life-threatening conditions are characterized by dysregulated immune responses including acute respiratory distress syndrome (ARDS), diabetic foot ulcers (DFU) and ulcerative colitis (UC), representing a US market of $4B. Affected tissues in these conditions all demonstrate reduce miR-146a and are corrected by our candidate drug products. Development to date has been supported by ~$7.5m of nondilutive financing and $500k investment capital. The company is seeking up to $3m in investment capital to contribute to a first-in-man clinical study of one drug product consisting of formulated CNP-miR-146a in DFU.

CellFE is a cell engineering startup that enables development and manufacturing of the new generation of medicines – cell therapies. CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering –efficiently delivering gene-editing molecules into cells while preserving cell viability. CellFE’s technology: • Enables development of previously inaccessible cell therapies by providing means for transporting hard-to-deliver molecules into the cells. • Accelerates commercialization of existing cell therapies by significantly reducing cost, complexity, and processing time, while improving the efficacy and safety of the cell engineering process.

Genomenon is a leading genomic intelligence company dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer. Blending the power of AI with genomic expertise, Genomenon simplifies complex genetic data into actionable insights for patient diagnosis and precision medicine development. The company’s solutions include software, data, and services. Genomenon offers advanced genomic software solutions designed to streamline and enhance genetic research and clinical decision-making. Our flagship product, the Mastermind® Genomic Intelligence Platform, provides comprehensive genomic data integration and analysis, offering researchers and clinicians a powerful tool to interpret genetic variants and their clinical relevance. Complementing this is the Cancer Knowledgebase (CKB), which focuses specifically on the landscape of somatic mutations, offering curated, actionable insights to support oncology research and personalized cancer treatment. Together, these platforms aim to accelerate discoveries and improve patient outcomes through sophisticated data analysis and knowledge integration.